Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA7 | P43166 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28613628 | 0.98 | TDP1 (0.38) | TDP1DGAT1CA1CA2CA7 | |
| SCHEMBL29930678 | 0.81 | TDP1 (0.37) | TDP1DGAT1CA1CA2CA7 | |
| SCHEMBL101218 | 0.73 | DGAT1 (0.46) | TDP1DGAT1CA1CA2CA7 | |
| SCHEMBL284141 | 0.73 | APLNR (0.55) | TDP1DGAT1CA1CA2CA7 | |
| SCHEMBL1950611 | 0.73 | — | — | |
| SCHEMBL1522412 | 0.70 | DGAT1 (0.44) | TDP1DGAT1CA1CA2CA7 | |
| SCHEMBL9409065 | 0.70 | — | — | |
| SCHEMBL6272856 | 0.70 | DGAT1 (0.44) | TDP1DGAT1CA1CA2CA7 | |
| SCHEMBL17960 | 0.70 | — | — | |
| SCHEMBL8428038 | 0.70 | DGAT1 (0.39) | TDP1DGAT1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3103792-A1 | INTERMEDIATES FOR THE PREPARATION OF 6-(7-((1-AMINOCYCLOPROPYL)METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1-NAPHTHAMIDE | Clovis Oncology Italy S.r.l. (IT) | 2016-12-14 | — | — | EP | disclosed |
| EP-2641897-B1 | A process for the preparation of 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl-1-naphthamide and synthetic intermediates thereof | CLOVIS ONCOLOGY ITALY S R L (IT) | 2016-07-13 | — | — | EP | disclosed |
| US-9340508-B2 | Process for the preparation of 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl-1-naphthamide and synthetic intermediates thereof | CLOVIS ONCOLOGY ITALY S.R.L. (IT) | 2016-05-17 | — | — | US | disclosed |
| US-20150191429-A1 | Process for the Preparation of 6-(7-((1-Aminocyclopropyl)Methoxy)-6-Methoxyquinolin-4-Yloxy)-N-Methyl-1-Naphthamide and Synthetic Intermediates Thereof | EOS ETHICAL ONCOLOGY SCIENCE, S.P.A., ABBREVIATED FORM EOS S.P.A. (IT) | 2015-07-09 | — | — | US | disclosed |
| US-9012645-B2 | Process for the preparation of 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl-1-naphthamide and synthetic intermediates thereof | CLOVIS ONCOLOGY ITALY S.R.L. (IT) | 2015-04-21 | — | — | US | disclosed |
| US-20140114075-A1 | PROCESS FOR THE PREPARATION OF 6-(7-((1-AMINOCYCLOPROPYL)METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1-NAPHTHAMIDE AND SYNTHETIC INTERMEDIATES THEREOF | EOS ETHICAL ONCOLOGY SCIENCE S.P.A. IN ABBREVIATED FORM EOS S.P.A. (IT) | 2014-04-24 | — | — | US | disclosed |
| US-8642767-B2 | Process for the preparation of 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl-1-naphthamide and synthetic intermediates thereof | EOS Ethical Oncology S.p.A. Abbreviated Form EOS S.p.A. (IT) | 2014-02-04 | — | — | US | disclosed |
| EP-2641897-A2 | A process for the preparation of 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl-1-naphthamide and synthetic intermediates thereof | EOS Ethical Oncology Science S.p.A. In Abbreviated From EOS S.p.A. (IT) | 2013-09-25 | — | — | EP | disclosed |
| EP-2408739-B1 | A PROCESS FOR THE PREPARATION OF 6-(7-((1-AMINOCYCLOPROPYL)METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1-NAPHTHAMIDE AND SYNTHETIC INTERMEDIATES THEREOF | EOS ETHICAL ONCOLOGY SCIENCE SPA IN ABBREVIATED FORM EOS SPA (IT) | 2013-08-14 | — | — | EP | disclosed |
| EP-2408739-A1 | A PROCESS FOR THE PREPARATION OF 6-(7-((1-AMINOCYCLOPROPYL)METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1-NAPHTHAMIDE AND SYNTHETIC INTERMEDIATES THEREOF | EOS Ethical Oncology Science S.p.A. In Abbreviated From EOS S.p.A. (IT) | 2012-01-25 | — | — | EP | disclosed |
| US-20120010415-A1 | PROCESS FOR THE PREPARATION OF 6-(7-((1-AMINOCYCLOPROPYL)METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1-NAPHTHAMIDE AND SYNTHETIC INTERMEDIATES THEREOF | CLOVIS ONCOLOGY ITALY S.R.L. (IT) | 2012-01-12 | — | — | US | disclosed |
| WO-2010105761-A1 | A PROCESS FOR THE PREPARATION OF 6-(7-((1-AMINOCYCLOPROPYL)METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1-NAPHTHAMIDE AND SYNTHETIC INTERMEDIATES THEREOF | EOS ETHICAL ONCOLOGY SCIENCE S.P.A. IN ABBREVIATED FORM EOS S.P.A. (IT) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140114075-A1 | PROCESS FOR THE PREPARATION OF 6-(7-((1-AMINOCYCLOPROPYL)METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1-NAPHTHAMIDE AND SYNTHETIC INTERMEDIATES THEREOF | CYP2B6, CYP2A6, NAT1 | TDP1 1490/4885DGAT1 2245/4885CA1 3573/4885 |
| US-20150191429-A1 | Process for the Preparation of 6-(7-((1-Aminocyclopropyl)Methoxy)-6-Methoxyquinolin-4-Yloxy)-N-Methyl-1-Naphthamide and Synthetic Intermediates Thereof | CYP2B6, CYP2A6, NAT1 | TDP1 1490/4885DGAT1 2245/4885CA1 3573/4885 |
| US-20120010415-A1 | PROCESS FOR THE PREPARATION OF 6-(7-((1-AMINOCYCLOPROPYL)METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1-NAPHTHAMIDE AND SYNTHETIC INTERMEDIATES THEREOF | CYP2B6, CYP2A6, NAT1 | TDP1 1519/4885DGAT1 2281/4885CA1 3579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.